XBiotech: W. Thorpe McKenzie reports 8.4% passive stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
XBiotech Inc. reports that W. Thorpe McKenzie beneficially owns 2,572,735 common shares, or 8.4% of the class. His reported position includes shares underlying stock options, including options immediately exercisable within 60 days of November 17, 2026, and 66,748 shares held by the McKenzie Foundation. McKenzie disclaims beneficial ownership of the Foundation shares except to the extent of his pecuniary interest.
For the reported percentage, the share-count basis includes 30,487,731 shares outstanding as of November 17, 2026, plus 237,500 shares issuable upon exercise of McKenzie's options. The filing reports 2,505,987 shares under his sole voting and dispositive power and 66,748 under shared voting and dispositive power.
Key Figures
Key Terms
beneficially owned regulatory
sole voting power regulatory
stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.